Moderately decreased cholesterol absorption rates are associated with a large atheroprotective effect

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 11, 2009, Pages 1745-1750

  Greenberg, Michael E ^a   Smith, Jonathan D ^a   Sehayek, Ephraim ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Absorption; Atherosclerosis; Cholesterol; Macrophage; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CHROMOSOME 14; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; LIPID ABSORPTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, CONGENIC; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; LIPID METABOLISM; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROBABILITY; RANDOM ALLOCATION; STATISTICS, NONPARAMETRIC;

EID: 73949102609     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.194605     Document Type: Article

References (19)

1. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106: 1943-1948.
2. Brown WV. Cholesterol absorption inhibitors: defining new options in lipid management. Clin Cardiol. 2003;26:259-264.
3. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008; 156:826-832.
4. Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359:1357-1366.
5. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duiven-voorden R, Veltri EP, Marais AD, de Groot E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358:1431-1443.
6. Davis HR Jr, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol. 2001;21: 2032-2038.
7. Ge L, Wang J, Qi W, Miao HH, Cao J, Qu YX, Li BL, Song BL. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 2008;7:508-519.
8. Sehayek E, Duncan EM, Lutjohann D, Von Bergmann K, Ono JG, Batta AK, Salen G, Breslow JL. Loci on chromosomes 14 and 2, distinct from ABCG5/ABCG8, regulate plasma plant sterol levels in a C57BL/6JXCASA/Rk intercross. Proc Natl Acad Sci USA. 2002;99: 16215-16219.
9. Sehayek E, Fung YY, Yu HJ, Lembcke J, Ceglarek U, Teupser D, Thiery J, Lutjohann D, von Bergmann K, Breslow JL. A complex plasma plant sterol locus on mouse chromosome 14 has at least two genes regulating intestinal sterol absorption. J Lipid Res. 2006;47:2291-2296.
10. Sehayek E, Ono JG, Shefer S, Nguyen LB, Wang N, Batta AK, Salen G, Smith JD, Tall AR, Breslow JL. Biliary cholesterol excretion: A novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci USA. 1998;95:10194-10199.
11. Smith JD, Peng DQ, Dansky HM, Settle M, Baglione J, Le Goff W, Chakrabarti E, Xu Y, Peng X. Transcriptome profile of macrophages from atherosclerosis-sensitive and atherosclerosis-resistant mice. Mamm Genome. 2006;17:220-229.
12. Hume DA, Allan W, Golder J, Stephens RW, Doe WF, Warren HS. Preparation and characterization of human bone marrow-derived macrophages. J Leukoc Biol. 1985;38:541-552.
13. Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol. 2008;28: 1296-1297.
14. Dansky HM, Charlton SA, Sikes JL, Heath SC, Simantov R, Levin LF, Shu P, Moore KJ, Breslow JL, Smith JD. Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 1999;19:1960-1968.
15. Sehayek E, Ono JG, Duncan EM, Batta AK, Salen G, Shefer S, Neguyen LB, Yang K, Lipkin M, Breslow JL. Hyodeoxycholic acid efficiently suppresses atherosclerosis formation and plasma cholesterol levels in mice. J Lipid Res. 2001;42:1250-1256.
16. Sehayek E, Shefer S, Nguyen LB, Ono JG, Merkel M, Breslow JL. Apolipoprotein E regulates dietary cholesterol absorption and biliary cholesterol excretion: Studies in C57BL/6 apolipoprotein E knockout mice. Proc Natl Acad Sci USA. 2000;97:3433-3437.
17. Woollett LA, Osono Y, Herz J, Dietschy JM. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc Natl Acad Sci USA. 1995;92:12500-12504.
18. Davis HR Jr, Hoos LM, Tetzloff G, Maguire M, Zhu LJ, Graziano MP, Altmann SW. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/-mice. Arterioscler Thromb Vasc Biol. 2007;27: 841-849.
19. Silbernagel G, Fauler G, Renner W, Landl EM, Hoffmann MM, Winkelmann BR, Boehm BO, Marz W. The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. J Lipid Res. 2009;50:334-341.